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Leukemia is a complex disease with many different types and subtypes caused by a huge
diversity of genetic and epigenetic aberrations. Until recently, alterations of protein-coding
genes were thought to be the sole cause of tumorigenesis. With the recent discovery of
multiple types of non-coding RNAs, it has become evident that mutations in these also
contribute to the development of cancer. Among the non-coding RNAs, microRNAs play a
crucial role in cancer owing to their involvement in fundamental processes such as
apoptosis, differentiation and proliferation [1,2].
MicroRNAs are small noncoding RNAs (approximately 19–25 nucleotides in length) that
bind to and downregulate multiple mRNA targets; in mammals, the production of over a
third of all proteins is regulated by microRNAs [3]. Several studies demonstrated that
microRNAs are involved in leukemia progression but their role as the primary cause or a
determinant of progression in leukemia has been unclear. Some have been identified as
oncogenes or tumor suppressor genes, which suggests that they are playing a central role in
tumorigenesis, while others appear to be associated with a specific stage in disease
progression. Deciphering the exact role of microRNAs in oncogenesis is important in order
to improve the diagnosis and treatment of leukemia patients.
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MicroRNAs: oncogenes & tumor suppressor genes
Several publications have showed that microRNAs function as oncogenes or tumor
suppressor genes [4]. By definition, the deletion or the downregulation of a tumor
suppressor gene leads to the activation of an oncogene. For example, miR-15a and miR-16-1
are frequently deleted in chronic lymphocytic leukemia (CLL) and their deletion leads to an
upregulation of the anti-apoptotic BCL-2 oncogene [5]. In mice, deletion of miR-15a and
miR-16-1 causes CLL [6].
On the other hand, an oncomiR is a microRNA whose upregulation promotes tumorigenesis
by downmodulating tumor suppressor genes. The first example of an oncomiR was
identified in 2005 with the description of the amplification of the polycistronic miR-17-92
cluster in B-cell lymphoma [7]. In mice, forced expression of miR-17-92 cooperates with c-
MYC to promote tumorigenesis [7]. In that scenario, miR-17-92 acts as a secondary event
with the ability to increase the oncogenicity of the c-MYC oncogene. A similar conclusion
was established with a transgenic mouse in which miR-155 was overexpressed in B cells [8].
These mice developed poly-clonal preleukemic pre-B-cell proliferation followed by B-cell
malignancy. This result suggests that miR-155 deregulation is an early event in the
oncogenic process and needs a secondary hit to generate a fully malignant phenotype. Han et
al. demonstrated that mice overexpressing miR-29a developed a myeloproliferative disorder
that progresses to acute myeloid leukemia (AML) [9].
We previously described the overexpression of miR-125b in patients with AML and
myelodysplasia with the t(2;11)(p21;q23) chromosomal translocation [10]. Mice
transplanted with hematopoietic progenitors overexpressing miR-125b showed an increase
in neutrophils and monocytes, associated with a macrocytic anemia [11]. Among these mice,
half of them died of B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic
leukemia, or a myeloproliferative neoplasm, suggesting an important role for miR-125b
early on in hematopoiesis [11]. It is likely that additional mutations contributed to the
leukemic transformation. Interestingly, O’Connell et al. and Ooi et al. used the same
strategy to study the role of miR-125b in vivo, but their results were different. O’Connell et
al. demonstrated that miR-125b overexpression led to AML in all mice but no leukemic
phenotype was observed in Ooi’s study [12,13]. As the major difference was the level of
overexpressed miR-125b, these results suggest that a microRNA can have different effects
depending on its level of expression and thus the numbers or types of mRNAs that are
downmodulated. In addition, we demonstrated that miR-125b was able to cooperate with
BCR-ABL to promote tumorigenesis in a transplanted mouse model [11]. This finding
suggests that miR-125b can also act as a secondary event in oncogenesis.
MicroRNA expression profile: a diagnostic tool?
The diagnosis and prognosis of leukemia currently depend on morphologic observation and
the detection of a variety of molecular and cytogenetic abnormalities. However, even in a
specific well-defined subtype there is significant variability between patients. The new level
of complexity added by microRNAs appears to be helpful in defining specific microRNA
signatures associated with predicting clinical outcomes. As microRNAs are usually
expressed in a lineage-specific manner, microRNA signatures have been employed to
differentiate AML from acute lymphoid leukemia (ALL) [14]. Indeed, expression profiling
revealed 27 microRNAs differentially expressed between AML and ALL. In particular,
miR-128a, miR-128b, miR-let-7b and miR-223 expression can distinguish AML from ALL,
with a diagnosis accuracy of >95% [14]. MicroRNA profiles can also identify different
subtypes of leukemia. For example, the tumor suppressors let-7b and let-7c are
downregulated in AML patients with t(8;21) and inv(16) [15]. MicroRNAs 382, 134, 376a,
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127, 299–5p and 323 are highly expressed in AML with the t(15;17) translocation [15].
Downregulation of miR-127 has been reported in AML with inv(16), while upregulation of
miR-155 has been identified in AML patients with the FLT3-ITD mutation [15,16].
Moreover, upregulation of microRNAs 10a, 10b, 196a and 196b and downregulation of
miR-204 and 128 are associated with NPM1 mutations in AML patients [15,16]. In AML
with CEBPA mutations, microRNAs 181a, 335 and 124 are upregulated [15,17]. In ALL
patients, eight microRNAs including miR-708 and miR-196b can distinguish subtypes of
ALL, with or without mixed lineage leukemia rearrangement [18]. Thus, the microRNA
expression profile can be used to define certain subtypes of leukemia, but additional studies
are needed to understand the involvement of these microRNAs in disease progression.
MicroRNA signatures: prognostic tool for disease progression
Calin et al. identified a unique signature of 13 microRNAs associated with prognostic
factors and disease progression in CLL. They screened 94 CLL patients and found that low
expression of miR-15a and miR-16-1 was associated with a good prognosis and
downregulation of microRNAs in the miR-29 family was associated with a poor prognosis
[19].
Another example is the upregulation of the miR-17–92 cluster, which has been reported in
the chronic phase but not during blast crisis of chronic myeloid leukemia (CML) [20].
Furthermore, downregulation of miR-17–92 was observed upon imatinib treatment in CML
cell lines, which suggests a control of the chronic phase by these microRNAs [20]. Eiring et
al. reported that low expression of miR-328 in CML is associated with progression to the
blast crisis phase of the disease [21]. Garzon et al. demonstrated that abnormally high levels
of miR-191 and miR-199a were associated with poor overall survival in patients with AML
[22].
Taking all these observations together, we conclude that microRNAs play a crucial role in
cancer. Similar to protein-coding genes, microRNAs participate both in the oncogenic
transformation event and in disease progression. Oncogenesis is a multi-step process which
includes an accumulation of mutations over time, and with most microRNAs it is still
difficult to decipher alterations in their expression as primary or secondary events.
Many signatures found in different subtypes of leukemia have been confirmed in multiple
studies, which suggests that changes in microRNA expression levels are actively involved in
the cancer process and are not just random events. We still need to discriminate between
microRNAs that are deregulated as a consequence of the disease state and microRNAs
whose deregulation contributes actively to disease progression. Some microRNAs, such as
miR-125b, appear to be sufficient to induce leukemia but we cannot exclude cooperation
with other mutations in the transformation process. We also do not know whether miR-125b
upregulation is necessary for disease initiation or progression.
Another layer of complexity is that some microRNAs can have different effects depending
on cellular context or expression level. For example, miR-29 is a tumor suppressor gene in
CLL, while in breast cancer it acts as an oncogene [23]. Similarly, miR-125b overexpression
causes leukemia but miR-125b downregulation was found to be associated with breast
cancer [11,24].
Identification of genes targeted for downregulation by oncogenic microRNAs will be an
important step in understanding their role in cancer. Mouse models are also useful but
sometimes differences in microRNA expression patterns or mRNA targets in different
species are a limitation. A better understanding of microRNA biology will help decipher the
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molecular mechanisms of tumorigenesis and define new therapeutic strategies against
cancer.
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